Download PDF
Semin Liver Dis 2012; 32(04): 317-324
DOI: 10.1055/s-0032-1329905
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

A Critical Appraisal of Advances in Pediatric Nonalcoholic Fatty Liver Disease

Nadia Ovchinsky
1   Department of Pediatrics, Columbia College of Physicians and Surgeons, Columbia University, New York, New York
,
Joel E. Lavine
1   Department of Pediatrics, Columbia College of Physicians and Surgeons, Columbia University, New York, New York
› Author Affiliations
Further Information

Publication History

Publication Date:
08 February 2013 (online)

    Permissions and Reprints

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of liver disease in children; its rise has been related to the increasing prevalence of obesity. Significant advancements have been made in the investigation of the etiopathogenesis and genetic risk factors for the disease. Pediatric fatty liver disease often displays a histologic pattern distinct from that found in adults, and liver biopsy remains the gold standard for diagnosis of nonalcoholic steatohepatitis (NASH). Lifestyle modifications that result in weight loss remain the first-line treatment of NAFLD in children. Recent adult and pediatric clinical trials on the use of antioxidants combined with lifestyle intervention for NAFLD have demonstrated encouraging results, and additional trials are underway. In this review, the authors provide an overview of current concepts in epidemiology, histologic features, diagnosis, pathophysiology, genetic risk factors, and treatment of NAFLD in children.

Keywords

nonalcoholic fatty liver disease (NAFLD) - nonalcoholic steatohepatitis (NASH) - pediatrics - obesity
 

  • References

  • 1 Ogden CL, Carroll MD, Curtin LR, Lamb MM, Flegal KM. Prevalence of high body mass index in US children and adolescents, 2007-2008. JAMA 2010; 303 (3) 242-249
    CrossrefPubMedGoogle Scholar
  • 2 Schwimmer JB, Behling C, Newbury R , et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 2005; 42 (3) 641-649
    CrossrefPubMedGoogle Scholar
  • 3 Brunt EM. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2010; 7 (4) 195-203
    CrossrefPubMedGoogle Scholar
  • 4 Schwimmer JB, Pardee PE, Lavine JE, Blumkin AK, Cook S. Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease. Circulation 2008; 118 (3) 277-283
    CrossrefPubMedGoogle Scholar
  • 5 Riley MR, Bass NM, Rosenthal P, Merriman RB. Underdiagnosis of pediatric obesity and underscreening for fatty liver disease and metabolic syndrome by pediatricians and pediatric subspecialists. J Pediatr 2005; 147 (6) 839-842
    PubMedGoogle Scholar
  • 6 Schwimmer JB, Dunn W, Norman GJ , et al. SAFETY study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease. Gastroenterology 2010; 138 (4) 1357-1364 , 1364, e1–e2
    CrossrefPubMedGoogle Scholar
  • 7 Manco M, Bedogni G, Marcellini M , et al. Waist circumference correlates with liver fibrosis in children with non-alcoholic steatohepatitis. Gut 2008; 57 (9) 1283-1287
    CrossrefPubMedGoogle Scholar
  • 8 Manco M, Marcellini M, Devito R , et al. Metabolic syndrome and liver histology in paediatric nonalcoholic steatohepatitis. Int J Obes 2008; 32: 381-387
    CrossrefPubMedGoogle Scholar
  • 9 Fraser A, Longnecker MP, Lawlor DA. Prevalence of elevated alanine aminotransferase among US adolescents and associated factors: NHANES 1999–2004. Gastroenterology 2007; 133 (6) 1814-1820
    CrossrefPubMedGoogle Scholar
  • 10 Wiegand S, Keller KM, Röbl M , et al; APV-Study Group and the German Competence Network Adipositas. Obese boys at increased risk for nonalcoholic liver disease: evaluation of 16,390 overweight or obese children and adolescents. Int J Obes (Lond) 2010; 34 (10) 1468-1474
    CrossrefPubMedGoogle Scholar
  • 11 Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics 2006; 118 (4) 1388-1393
    CrossrefPubMedGoogle Scholar
  • 12 Patton HM, Lavine JE, Van Natta ML, Schwimmer JB, Kleiner D, Molleston J. Nonalcoholic Steatohepatitis Clinical Research Network. Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis. Gastroenterology 2008; 135 (6) 1961-1971 , e2
    CrossrefPubMedGoogle Scholar
  • 13 Barlow SE. Expert Committee. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics 2007; 120 (Suppl. 04) S164-S192
    CrossrefPubMedGoogle Scholar
  • 14 Chalasani N, Younossi Z, Lavine JE , et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55 (6) 2005-2023
    CrossrefPubMedGoogle Scholar
  • 15 Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, Benson JT, Enders FB, Angulo P. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut 2009; 58 (11) 1538-1544
    CrossrefPubMedGoogle Scholar
  • 16 Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol 2009; 51 (2) 371-379
    CrossrefPubMedGoogle Scholar
  • 17 Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51 (6) 1972-1978
    CrossrefPubMedGoogle Scholar
  • 18 Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010; 51 (5) 1820-1832
    CrossrefPubMedGoogle Scholar
  • 19 Sanyal A, Poklepovic A, Moyneur E, Barghout V. Population-based risk factors and resource utilization for HCC: US perspective. Curr Med Res Opin 2010; 26 (9) 2183-2191
    CrossrefPubMedGoogle Scholar
  • 20 Argo CK, Caldwell SH. Epidemiology and natural history of non-alcoholic steatohepatitis. Clin Liver Dis 2009; 13 (4) 511-531
    CrossrefPubMedGoogle Scholar
  • 21 Caserta CA, Pendino GM, Amante A , et al. Cardiovascular risk factors, nonalcoholic fatty liver disease, and carotid artery intima-media thickness in an adolescent population in southern Italy. Am J Epidemiol 2010; 171 (11) 1195-1202
    CrossrefPubMedGoogle Scholar
  • 22 Demircioğlu F, Koçyiğit A, Arslan N, Cakmakçi H, Hizli S, Sedat AT. Intima-media thickness of carotid artery and susceptibility to atherosclerosis in obese children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2008; 47 (1) 68-75
    CrossrefPubMedGoogle Scholar
  • 23 Pacifico L, Cantisani V, Ricci P , et al. Nonalcoholic fatty liver disease and carotid atherosclerosis in children. Pediatr Res 2008; 63 (4) 423-427
    CrossrefPubMedGoogle Scholar
  • 24 Pacifico L, Anania C, Martino F , et al. Functional and morphological vascular changes in pediatric nonalcoholic fatty liver disease. Hepatology 2010; 52 (5) 1643-1651
    CrossrefPubMedGoogle Scholar
  • 25 Kleiner DE, Brunt EM, Van Natta M , et al; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41 (6) 1313-1321
    CrossrefPubMedGoogle Scholar
  • 26 Wong VW, Wong GL, Choi PC , et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 2010; 59 (7) 969-974
    CrossrefPubMedGoogle Scholar
  • 27 Carter-Kent C, Yerian LM, Brunt EM , et al. Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study. Hepatology 2009; 50 (4) 1113-1120
    CrossrefPubMedGoogle Scholar
  • 28 Nobili V, Pinzani M. Paediatric non-alcoholic fatty liver disease. Gut 2010; 59 (5) 561-564
    CrossrefPubMedGoogle Scholar
  • 29 Pacifico L, Celestre M, Anania C, Paolantonio P, Chiesa C, Laghi A. MRI and ultrasound for hepatic fat quantification: relationships to clinical and metabolic characteristics of pediatric nonalcoholic fatty liver disease. Acta Paediatr 2007; 96 (4) 542-547
    CrossrefPubMedGoogle Scholar
  • 30 Schwimmer JB, Celedon MA, Lavine JE , et al. Heritability of nonalcoholic fatty liver disease. Gastroenterology 2009; 136 (5) 1585-1592
    CrossrefPubMedGoogle Scholar
  • 31 Nguyen D, Talwalkar JA. Noninvasive assessment of liver fibrosis. Hepatology 2011; 53 (6) 2107-2110
    CrossrefPubMedGoogle Scholar
  • 32 Nobili V, Vizzutti F, Arena U , et al. Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology 2008; 48 (2) 442-448
    CrossrefPubMedGoogle Scholar
  • 33 de Lédinghen V, Le Bail B, Rebouissoux L , et al. Liver stiffness measurement in children using FibroScan: feasibility study and comparison with Fibrotest, aspartate transaminase to platelets ratio index, and liver biopsy. J Pediatr Gastroenterol Nutr 2007; 45 (4) 443-450
    CrossrefPubMedGoogle Scholar
  • 34 Rockey DC, Bissell DM. Noninvasive measures of liver fibrosis. Hepatology 2006; 43 (2) (Suppl. 01) S113-S120
    CrossrefPubMedGoogle Scholar
  • 35 Huwart L, Sempoux C, Vicaut E , et al. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology 2008; 135 (1) 32-40
    CrossrefPubMedGoogle Scholar
  • 36 Yin M, Talwalkar JA, Glaser KJ , et al. Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol 2007; 5 (10) 1207-1213 , e2
    CrossrefPubMedGoogle Scholar
  • 37 Chen J, Talwalkar JA, Yin M, Glaser KJ, Sanderson SO, Ehman RL. Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology 2011; 259 (3) 749-756
    CrossrefPubMedGoogle Scholar
  • 38 Imbert-Bismut F, Messous D, Thibault V , et al. Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors. Clin Chem Lab Med 2004; 42 (3) 323-333
    CrossrefPubMedGoogle Scholar
  • 39 Friedrich-Rust M, Rosenberg W, Parkes J, Herrmann E, Zeuzem S, Sarrazin C. Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis. BMC Gastroenterol 2010; 10: 103
    CrossrefPubMedGoogle Scholar
  • 40 Halfon P, Bourliere M, Deydier R , et al. Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study. Am J Gastroenterol 2006; 101 (3) 547-555
    CrossrefPubMedGoogle Scholar
  • 41 Guha IN, Parkes J, Roderick P , et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008; 47 (2) 455-460
    CrossrefPubMedGoogle Scholar
  • 42 Nobili V, Parkes J, Bottazzo G , et al. Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease. Gastroenterology 2009; 136 (1) 160-167
    CrossrefPubMedGoogle Scholar
  • 43 Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009; 50 (4) 1072-1078
    CrossrefPubMedGoogle Scholar
  • 44 Seidel N, Volkmann X, Länger F , et al. The extent of liver steatosis in chronic hepatitis C virus infection is mirrored by caspase activity in serum. Hepatology 2005; 42 (1) 113-120
    CrossrefPubMedGoogle Scholar
  • 45 Valva P, De Matteo E, Galoppo MC, Gismondi MI, Preciado MV. Apoptosis markers related to pathogenesis of pediatric chronic hepatitis C virus infection: M30 mirrors the severity of steatosis. J Med Virol 2010; 82 (6) 949-957
    CrossrefPubMedGoogle Scholar
  • 46 Joka D, Wahl K, Moeller S , et al. Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis. Hepatology 2012; 55 (2) 455-464
    CrossrefPubMedGoogle Scholar
  • 47 Adams LA. Biomarkers of liver fibrosis. J Gastroenterol Hepatol 2011; 26 (5) 802-809
    CrossrefPubMedGoogle Scholar
  • 48 Bell LN, Theodorakis JL, Vuppalanchi R , et al. Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease. Hepatology 2010; 51 (1) 111-120
    CrossrefPubMedGoogle Scholar
  • 49 Morra R, Munteanu M, Bedossa P , et al. Diagnostic value of serum protein profiling by SELDI-TOF ProteinChip compared with a biochemical marker, FibroTest, for the diagnosis of advanced fibrosis in patients with chronic hepatitis C. Aliment Pharmacol Ther 2007; 26 (6) 847-858
    CrossrefPubMedGoogle Scholar
  • 50 Poon TC, Hui AY, Chan HL , et al. Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection by serum proteomic fingerprinting: a pilot study. Clin Chem 2005; 51 (2) 328-335
    CrossrefPubMedGoogle Scholar
  • 51 Ouyang X, Cirillo P, Sautin Y , et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol 2008; 48 (6) 993-999
    CrossrefPubMedGoogle Scholar
  • 52 Lindbäck SM, Gabbert C, Johnson BL , et al. Pediatric nonalcoholic fatty liver disease: a comprehensive review. Adv Pediatr 2010; 57 (1) 85-140
    CrossrefPubMedGoogle Scholar
  • 53 Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science 2011; 332 (6037) 1519-1523
    CrossrefPubMedGoogle Scholar
  • 54 Lim JS, Mietus-Snyder M, Valente A, Schwarz JM, Lustig RH. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gastroenterol Hepatol 2010; 7 (5) 251-264
    CrossrefPubMedGoogle Scholar
  • 55 Nielsen SJ, Popkin BM. Changes in beverage intake between 1977 and 2001. Am J Prev Med 2004; 27 (3) 205-210
    CrossrefPubMedGoogle Scholar
  • 56 Hu FB, Malik VS. Sugar-sweetened beverages and risk of obesity and type 2 diabetes: epidemiologic evidence. Physiol Behav 2010; 100 (1) 47-54
    CrossrefPubMedGoogle Scholar
  • 57 Vega GL, Chandalia M, Szczepaniak LS, Grundy SM. Metabolic correlates of nonalcoholic fatty liver in women and men. Hepatology 2007; 46 (3) 716-722
    CrossrefPubMedGoogle Scholar
  • 58 Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010; 52 (5) 1836-1846
    CrossrefPubMedGoogle Scholar
  • 59 Ye J, Gao Z, Yin J, He Q. Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. Am J Physiol Endocrinol Metab 2007; 293 (4) E1118-E1128
    CrossrefPubMedGoogle Scholar
  • 60 Polyzos SA, Kountouras J, Zavos C, Deretzi G. The potential adverse role of leptin resistance in nonalcoholic fatty liver disease: a hypothesis based on critical review of the literature. J Clin Gastroenterol 2011; 45 (1) 50-54
    CrossrefPubMedGoogle Scholar
  • 61 Choi SS, Syn WK, Karaca GF , et al. Leptin promotes the myofibroblastic phenotype in hepatic stellate cells by activating the hedgehog pathway. J Biol Chem 2010; 285 (47) 36551-36560
    CrossrefPubMedGoogle Scholar
  • 62 De Minicis S, Seki E, Oesterreicher C, Schnabl B, Schwabe RF, Brenner DA. Reduced nicotinamide adenine dinucleotide phosphate oxidase mediates fibrotic and inflammatory effects of leptin on hepatic stellate cells. Hepatology 2008; 48 (6) 2016-2026
    CrossrefPubMedGoogle Scholar
  • 63 Wang SN, Lee KT, Ker CG. Leptin in hepatocellular carcinoma. World J Gastroenterol 2010; 16 (46) 5801-5809
    CrossrefPubMedGoogle Scholar
  • 64 Tilg H. The role of cytokines in non-alcoholic fatty liver disease. Dig Dis 2010; 28 (1) 179-185
    CrossrefPubMedGoogle Scholar
  • 65 Pagano C, Soardo G, Esposito W , et al. Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur J Endocrinol 2005; 152 (1) 113-118
    CrossrefPubMedGoogle Scholar
  • 66 Pisto P, Ukkola O, Santaniemi M, Kesäniemi YA. Plasma adiponectin—an independent indicator of liver fat accumulation. Metabolism 2011; 60 (11) 1515-1520
    CrossrefPubMedGoogle Scholar
  • 67 Tilg H. Obesity, metabolic syndrome, and microbiota: multiple interactions. J Clin Gastroenterol 2010; 44 (Suppl. 01) S16-S18
    CrossrefPubMedGoogle Scholar
  • 68 Abu-Shanab A, Quigley EM. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2010; 7 (12) 691-701
    CrossrefPubMedGoogle Scholar
  • 69 Burke CA. Colonic complications of obesity. Gastroenterol Clin North Am 2010; 39 (1) 47-55
    CrossrefPubMedGoogle Scholar
  • 70 Spruss A, Kanuri G, Wagnerberger S, Haub S, Bischoff SC, Bergheim I. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology 2009; 50 (4) 1094-1104
    CrossrefPubMedGoogle Scholar
  • 71 Harte AL, da Silva NF, Creely SJ , et al. Elevated endotoxin levels in non-alcoholic fatty liver disease. J Inflamm (Lond) 2010; 7: 15
    CrossrefPubMedGoogle Scholar
  • 72 Dasu MR, Devaraj S, Park S, Jialal I. Increased toll-like receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects. Diabetes Care 2010; 33 (4) 861-868
    CrossrefPubMedGoogle Scholar
  • 73 Alisi A, Manco M, Devito R, Piemonte F, Nobili V. Endotoxin and plasminogen activator inhibitor-1 serum levels associated with nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr 2010; 50 (6) 645-649
    CrossrefPubMedGoogle Scholar
  • 74 Schwimmer JB, Celedon MA, Lavine JE , et al. Heritability of nonalcoholic fatty liver disease. Gastroenterology 2009; 136 (5) 1585-1592
    CrossrefPubMedGoogle Scholar
  • 75 Rotman Y, Koh C, Zmuda JM, Kleiner DE, Liang TJ. NASH CRN. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 2010; 52 (3) 894-903
    CrossrefPubMedGoogle Scholar
  • 76 Romeo S, Kozlitina J, Xing C , et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40 (12) 1461-1465
    CrossrefPubMedGoogle Scholar
  • 77 Romeo S, Sentinelli F, Cambuli VM , et al. The 148M allele of the PNPLA3 gene is associated with indices of liver damage early in life. J Hepatol 2010; 53 (2) 335-338
    CrossrefPubMedGoogle Scholar
  • 78 Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011; 53 (6) 1883-1894
    CrossrefPubMedGoogle Scholar
  • 79 Speliotes EK, Yerges-Armstrong LM, Wu J , et al; NASH CRN; GIANT Consortium; MAGIC Investigators; GOLD Consortium. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 2011; 7 (3) e1001324
    CrossrefPubMedGoogle Scholar
  • 80 Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology 2008; 134 (6) 1682-1698
    CrossrefPubMedGoogle Scholar
  • 81 Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 2012; 55 (4) 885-904
    CrossrefPubMedGoogle Scholar
  • 82 Thoma C, Day CP, Trenell MI. Lifestyle interventions for the treatment of nonalcoholic fatty liver disease in adults: a systematic review. J Hepatol 2012; 2012 (56) 255-266
    PubMedGoogle Scholar
  • 83 Sato F, Tamura Y, Watada H , et al. Effects of diet-induced moderate weight reduction on intrahepatic and intramyocellular triglycerides and glucose metabolism in obese subjects. J Clin Endocrinol Metab 2007; 92 (8) 3326-3329
    CrossrefPubMedGoogle Scholar
  • 84 Keating SE, Hackett DA, George J, Johnson NA. Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 2012; 57 (1) 157-166
    CrossrefPubMedGoogle Scholar
  • 85 Nobili V, Marcellini M, Devito R , et al. NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice. Hepatology 2006; 44 (2) 458-465
    CrossrefPubMedGoogle Scholar
  • 86 Grønbæk H, Lange A, Birkebæk NH , et al. Effect of a 10-week weight loss camp on fatty liver disease and insulin sensitivity in obese Danish children. J Pediatr Gastroenterol Nutr 2012; 54 (2) 223-228
    CrossrefPubMedGoogle Scholar
  • 87 Barker KB, Palekar NA, Bowers SP, Goldberg JE, Pulcini JP, Harrison SA. Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery. Am J Gastroenterol 2006; 101 (2) 368-373
    CrossrefPubMedGoogle Scholar
  • 88 Pardee PE, Lavine JE, Schwimmer JB. Diagnosis and treatment of pediatric nonalcoholic steatohepatitis and the implications for bariatric surgery. Semin Pediatr Surg 2009; 18 (3) 144-151
    CrossrefPubMedGoogle Scholar
  • 89 Weiner RA. Surgical treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease. Dig Dis 2010; 28 (1) 274-279
    CrossrefPubMedGoogle Scholar
  • 90 Nadler EP, Youn HA, Ren CJ, Fielding GA. An update on 73 US obese pediatric patients treated with laparoscopic adjustable gastric banding: comorbidity resolution and compliance data. J Pediatr Surg 2008; 43 (1) 141-146
    CrossrefPubMedGoogle Scholar
  • 91 Nadler EP, Reddy S, Isenalumhe A , et al. Laparoscopic adjustable gastric banding for morbidly obese adolescents affects android fat loss, resolution of comorbidities, and improved metabolic status. J Am Coll Surg 2009; 209 (5) 638-644
    CrossrefPubMedGoogle Scholar
  • 92 Klein-Platat C, Drai J, Oujaa M, Schlienger JL, Simon C. Plasma fatty acid composition is associated with the metabolic syndrome and low-grade inflammation in overweight adolescents. Am J Clin Nutr 2005; 82 (6) 1178-1184
    PubMedGoogle Scholar
  • 93 Capanni M, Calella F, Biagini MR , et al. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther 2006; 23 (8) 1143-1151
    CrossrefPubMedGoogle Scholar
  • 94 Spadaro L, Magliocco O, Spampinato D , et al. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig Liver Dis 2008; 40 (3) 194-199
    CrossrefPubMedGoogle Scholar
  • 95 Nobili V, Bedogni G, Alisi A , et al. Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial. Arch Dis Child 2011; 96 (4) 350-353
    CrossrefPubMedGoogle Scholar
  • 96 Sanyal AJ, Chalasani N, Kowdley KV , et al; NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362 (18) 1675-1685
    CrossrefPubMedGoogle Scholar
  • 97 Lavine JE, Schwimmer JB, Van Natta ML , et al; Nonalcoholic Steatohepatitis Clinical Research Network. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011; 305 (16) 1659-1668
    CrossrefPubMedGoogle Scholar
  • 98 Dohil R, Fidler M, Gangoiti JA, Kaskel F, Schneider JA, Barshop BA. Twice-daily cysteamine bitartrate therapy for children with cystinosis. J Pediatr 2010; 156 (1) 71-75 , e1–e3
    PubMedGoogle Scholar
  • 99 Lu SC. Regulation of glutathione synthesis. Mol Aspects Med 2009; 30 (1–2) 42-59
    CrossrefPubMedGoogle Scholar
  • 100 Dohil R, Schmeltzer S, Cabrera BL , et al. Enteric-coated cysteamine for the treatment of paediatric non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2011; 33 (9) 1036-1044
    CrossrefPubMedGoogle Scholar
  • 101 Dohil R, Meyer L, Schmeltzer S, Cabrera BL, Lavine JE, Phillips SA. The Effect of Cysteamine Bitartrate on Adiponectin Multimerization in Non-Alcoholic Fatty Liver Disease and Healthy Subjects. J Pediatr 2012; . [Epub ahead of print]
    PubMedGoogle Scholar
  • 102 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). NIH study to test treatment of fatty liver disease in children. Available at: http://www.nih.gov/news/health/jan2012/niddk-11.htm . Accessed January 30, 2012
    PubMedGoogle Scholar